Redeye believes Sdiptech’s acquisition of JR Industries looks solid.
We update our estimates ahead of Arise’s Q4 report on the back of the recently published production ...
Q4'23 results due 6 February Already pre-announced strong sales for Oct-Nov Fully focused US orthobi...
Prel. Q4 figures: EE 3.7m, revenue SEK 37m, EBIT SEK 15.
Chordate Medical AB (”Chordate” eller ”bolaget”) är verksamma inom medicinteknikbranschen, och bolag...
Vitrolife provides an update ahead of the total Q4 due on 2 February.
Encouraged by the acquisition of Kammac, we raise adjusted EBIT by 14-15% for 2024E-25E ahead of Ela...
Starts deploying its cash pile... ...and executing on M&A-focused growth strategy.
Q4e: sales SEK 574m, -3% y-o-y, SEK 60m material sales in comps Tougher comps and an EMS slowdown af...
SEK 4.3bn impairment charge of Igenomix 1.6% beat on preliminary Q4 adj EBITDA Minor positive earnin...
Q4e: Clean EBIT of PLN 87m Paper markets still weak, but demand better Fair value range of SEK 40-80...
Det svenska sensorteknikbolaget JonDeTech Sensors AB (”JonDeTech” eller ”Bolaget”) designar, produce...
Redeye comments on Sleep Cycle’s announcement this morning regarding its strategic move to consolida...
Redeye comments on the directed share issue that completes the previous rights issue.
Q4 report due Friday, 23 February at 07:00 CET 6.0-9.
Q4 report due 29 Feb Q4'23e net sales of SEK 464m, EBITA of SEK 59m We estimate the fair value at SE...
Redeye endorses today’s news that Curasight has received the first milestone payment from Curium and...
Equity analyst Markus Almerud interviews Maha’s CEO Kjetil Solbraekke about the acquisition of 5% of...
Redeye leave a comment on Xbrane following today's announcement of a SEK343m rights issue of units.
'23e-'25e EBITA down 8-3% Gross margin recovery hampered by Red Sea tensions '24e-'25e lease adj.
